Screening of melatonin, α-tocopherol, folic acid, acetyl-l-carnitine and resveratrol for anti-dengue 2 virus activity

被引：25

作者：

Paemanee A. ^{[1
,2
]}

Hitakarun A. ^{[1
]}

Roytrakul S. ^{[2
]}

Smith D.R. ^{[1
]}

机构：

[1] Molecular Pathology Laboratory, Institute of Molecular Biosciences, Mahidol University, Salaya Campus, 25/25 Phuttamonthol Sai 4, Salaya Nakorn Pathom

[2] Proteomics Research Laboratory, Genome Technology Research Unit, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, 113 Thailand Science Park, Phahonyothin Road, Khlong Nueng, Khlong Luang Pathumt

来源：

BMC Research Notes | / 11卷 / 1期

关键词：

Acetyl-l-carnitine; Dengue virus; Flavivirus; Folic acid; Melatonin; Resveratrol; α-Tocopherol;

D O I：

10.1186/s13104-018-3417-3

中图分类号：

学科分类号：

摘要：

Objective: Infections with the mosquito transmitted dengue virus (DENV) are a significant public health burden in many parts of the world. Despite the introduction of a commercial vaccine in some parts of the world, the majority of the populations at risk of infection remain unprotected against this disease, and there is currently no treatment for DENV infection. Natural compounds offer the prospect of cheap and sustainable therapeutics to reduce the disease burden during infection, and thus potentially alleviate the risk of more severe disease. This study evaluated the potential anti-DENV 2 activity of five natural compounds namely melatonin, α-tocopherol, folic acid, acetyl-l-carnitine and resveratrol in two different cell lines. Results: Screening of the compounds showed that one compound (acetyl-l-carnitine) showed no effect on DENV infection, three compounds (melatonin, α-tocopherol and folic acid) slightly increased levels of infection, while the 5th compound, resveratrol, showed some limited anti-DENV activity, with resveratrol reducing virus output with an EC50 of less than 25 μM. These results suggest that some commonly taken natural compounds may have beneficial effects on DENV infection, but that others may potentially add to the disease burden. © 2018 The Author(s).

引用

共 41 条

[1]

Murray N.E.A., Quam M.B., Wilder-Smith A., Epidemiology of dengue: Past, present and future prospects, Clin Epidemiol, 5, (2013)

[2]

Gubler D.J., Dengue and dengue hemorrhagic fever, Clin Microbiol Rev, 11, pp. 480-496, (1998)

[3]

Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., Drake J.M., Brownstein J.S., Hoen A.G., Sankoh O., The global distribution and burden of dengue, Nature, 496, pp. 504-507, (2013)

[4]

Gubler D.J., Dengue, urbanization and globalization: The unholy trinity of the 21st century, Trop Med Health, 39, pp. S3-S11, (2011)

[5]

Brady O.J., Gething P.W., Bhatt S., Messina J.P., Brownstein J.S., Hoen A.G., Moyes C.L., Farlow A.W., Scott T.W., Hay S.I., Refining the global spatial limits of dengue virus transmission by evidence-based consensus, PLoS Negl Trop Dis, 6, (2012)

[6]

Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control, (2009)

[7]

Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., Endy T.P., Raengsakulrach B., Rothman A.L., Ennis F.A., Nisalak A., Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity, J Infect Dis, 181, pp. 2-9, (2000)

[8]

Avorn J., The $2.6 billion pill - Methodologic and policy considerations, N Engl J Med, 372, pp. 1877-1879, (2015)

[9]

Sithisarn P., Suksanpaisan L., Thepparit C., Smith D.R., Behavior of the dengue virus in solution, J Med Virol, 71, pp. 532-539, (2003)

[10]

Henchal E.A., Gentry M.K., McCown J.M., Brandt W.E., Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence, Am J Trop Med Hyg, 31, pp. 830-836, (1982)

← 1 2 3 4 5 →